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Lovastatin biosynthesis in Aspergillus terreus: characterization 
of blocked mutants, enzyme activities and a multifunctional 
polyketide synthase gene 
Lee Hendrickson’, C Ray Davis *, Claudia Roach3, Di Kim Nguyen3, 
Teri Aldrich*, Phyllis C McAda4 and Christopher D Reeves5 
Background: Lovastatin, an HMG-CoA reductase inhibitor produced by the 
fungus Aspergillus teneus, is composed of two polyketide chains. One is a 
nonaketide that undergoes cyclization to a hexahydronaphthalene ring system 
and the other is a simple diketide, 2-methylbutyrate. Fungal polyketide synthase 
(PKS) systems are of great interest and their genetic manipulation should lead 
to novel compounds. 
Results: An A. terreus mutant (BX102) was isolated that could not synthesize the 
nonaketide portion of lovastatin and was missing a -250 kDa polypeptide normally 
present under conditions of lovastatin production. Other mutants produced 
lovastatin intermediates without the methylbutyryl sidechain and were missing a 
polypeptide of -220 kDa. The PKS inhibitor cerulenin reacted covalently with both 
polypeptides. Antiserum raised against the -250 kDa polypeptide was used to 
isolate the corresponding gene, which complemented the BX102 mutation. The 
gene encodes a polypeptide of 269 kDa containing catalytic domains typical of 
vertebrate fatty acid and fungal PKSs, plus two additional domains not previously 
seen in PKSs: a centrally located methyltransferase domain and a peptide 
synthetase elongation domain at the carboxyl terminus. 
Conclusions: The results show that the nonaketide and diketide portions of 
lovastatin are synthesized by separate large multifunctional PKSs. Elucidation 
of the primary structure of the PKS that forms the lovastatin nonaketide, as 
well as characterization of blocked mutants, provides new details of lovastatin 
biosynthesis. 
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Introduction 
Lovastatin (also known as mevinolin, Mevacor and mona- 
colin K), an inhibitor of HMG-CoA reductase produced by 
Aspe&hs terreus and other fungi, is used to reduce serum 
cholesterol levels in humans [l]. It is biosynthetically 
derived from two polyketide chains joined through an 
ester linkage [Z-S]. One chain is the diketide Z-methylbu- 
tyrate and the other is a nonaketide that includes a distinc- 
tive conjugated hexahydronaphthalene ring system. 
Over the past several years it has become clear that polyke- 
tides are assembled in a variety of mechanistically complex 
ways [6]. Polyketide synthases (PKSs) are structurally and 
functionally related to the fatty acid synthases (FASs), both 
catalyzing sequential decarboxylative condensations 
between ACP-linked acyl-thioesters. Unlike most FASs, 
however, PKSs can omit some or all of the reduction reac- 
tions (P-keto reduction, dehydration and enoyl reduction) 
that take place after each condensation, thereby yielding 
products with ketone, alcohol or alkene instead of methyl- 
ene functional groups at specific positions along the chain. 
There are at least three types of PKS systems [6]: the itera- 
tive type II systems of actinomycetes, which generally 
produce aromatic structures such as actinorhodin or tetra- 
cenomycin; the modular type I systems of actinomycetes, 
which produce macrolides such as erythromycin; and the 
iterative type I systems typical in fungi, which produce 
precursors to widely different structures such as patulin, 
sterigmatocystin or lovastatin. 
Figure 1 shows an overall scheme for lovastatin biosynthe- 
sis, incorporating data from isotope labeling studies [Z-5], 
biotransformation of intermediates [7-91 and this work. 
Important details of this pathway, such as the C-methyla- 
tion reactions, the transition from reduced to more oxi- 
dized carbons in the nonaketide and cyclization to the 
unusual hexahydronaphthalene ring system, proposed to 
involve a Diels-Alder condensation [Z-S], have remained 
poorly understood. Studies of lovastatin biosynthesis 
should provide new insights into the complex structure- 
function relationships of iterative multifunctional PKS 
systems. As a first step towards elucidating the enzymology 
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Figure 1 
Hypothetical pathway for lovastatin 
biosynthesis. independent pathways form the 
diketide (blue) and nonaketide (green) 
portions of lovastatin, which we propose are 
catalyzed by lovastatin diketide synthase 
(LDKS) and lovastatin nonaketide synthase 
(LNKS), respectively. Both enzymes build their 
polyketide product from an acetyl starter unit 
Monacolin L 
and malonyl extender units, and both add a 





v Methylbutyryl transferase 
H”yCOOH 
(shown in yellow). The intermediates shown 
bound to the PKSs are hypothetical, but 
consistent with results described here. 
Cyclization via a Diels-Alder condensation is 
not proven, but is the current hypothesis. The 
oxygen in red is derived from a P450 
oxidation. Details shown in this figure are 
discussed in the text. 
Dihydromonacolin L 
OH 0 
ULDKS + dLDKS + 2LDKS 
Lovastatin 
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of lovastatin biosynthesis, we isolated mutants of A. [eveus 
that no longer produced lovastatin. Using these mutants, 
the gene for the PKS involved in synthesis of the nonake- 
tide portion of lovastatin was cloned and characterized, 
suggesting new details of lovastatin biosynthesis. 
Results 
Isolation of mutants blocked in lovastatin biosynthesis 
In a mutagenesis and screening effort aimed at increasing 
lovastatin titer, A. terreus mutants were found that did not 
produce lovastatin. In this effort lovastatin and its biosyn- 
thetic intermediates were resolved using high-perfor- 
mance liquid chromatography (HPLC) and quantitated by 
absorbance at 239 nm. The mutants were derived from a 
lovastatin-producing strain designated CW. Five mutants 
produced monacolin J at about 60% the level of lovastatin- 
produced by strain CW, and low levels of monacolin L. 
These mutants appeared at a higher than expected fre- 
quency, suggesting a mutational hot spot. This phenotype 
indicates a mutation in a gene encoding either synthesis of 
the methylbutyryl group or its transfer to monacolin J to 
give lovastatin. One mutant was isolated that produced 
monacolin X (lovastatin with a methyl-acetoacetyl 
sidechain instead of a methylbutyryl sidechain, as first 
observed in cultures of wild-type Monascus r&r [lo]), plus 
monacolin J, the titers being about 40% and lo%, respec- 
tively, of the lovastatin titer produced by strain CW. This 
phenotype most probably results from a defect in the 
ketoreductase domain of the lovastatin PKS. 
Another mutant was identified that produced no detectable 
metabolite with the characteristic UV absorbance spectrum 
of lovastatin intermediates. This mutant (BXlOZ) produced 
other metabolites derived from the polyketide emodin, as 
reported for lovastatin production strains [ 111, indicating 
that they had not suffered a general loss of secondary 
metabolite production. Moreover, if cultures of BX102 
were fed monacolin J, they efficiently converted it to lovas- 
tatin, indicating that the genes for synthesis and attach- 
ment of the methylbutyryl group were functionally 
expressed. Strain BX102 was therefore defective in a gene 
encoding an enzyme catalyzing the synthesis of the nona- 
ketide portion of lovastatin. Because mutants were defec- 
tive in synthesis of either the diketide or the nonaketide 
without affecting the other pathway, the biosynthetic path- 
ways for these two portions of lovastatin are independent 
and utilize separate enzymes. We call the corresponding 
PKSs lovastatin nonaketide synthase (LNKS) and lovas- 
tatin diketide synthase (LDKS). 
Identification of lovastatin biosynthetic activities in cell- 
free extracts 
To assay lovastatin PKSs, cell-free extracts were incu- 
bated in a reaction mixture that included [‘“Clmalonyl- 
CoA, acetyl-CoA, S-adenosyl methionine, NADPH and 
ATP. The labeled products were extracted with ethyl 
acetate, resolved using HPLC and counted for 14C incor- 
poration. Extracts of strain CW incorporated radioactivity 
into components eluting with the retention times of lovas- 
tatin carboxylate, lovastatin lactone and palmitic acid, 
whereas extracts of strain BX102 grown under the same 
conditions incorporated label into the peak co-eluting 
with palmitic acid, but not into lovastatin (Figure 2). The 
labeled products co-eluting with lovastatin carboxylate 
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and lovastatin lactone were isolated and shown to be con- 
verted into the other form by incubation at pH extremes. 
We therefore showed that in vitro synthesis of lovastatin 
was occurring in cell-free extracts. Incorporation of labeled 
malonyl-CoA into lovastatin did not occur if any of the 
cofactors (including ATP) were omitted. Cerulenin (at 
1 mM), a specific inhibitor of polyketide and fatty acid 
synthases [ 121, completely inhibited incorporation of 
[14C]malonyl-CoA into both lovastatin and palmitic acid. 
In attempts to purify the predicted lovastatin PKSs, crude 
extracts were subjected to several types of chromatography 
and fractions were assayed for incorporation of 
[14C]malonyl-CoA into ethyl acetate extractable products, 
as detected by autoradiography of thin-layer chro- 
matograms. Although particular column fractions did show 
NADPH-dependent incorporation of malonyl-CoA into 
specific ethyl acetate extractable products, indicative of 
possible lovastatin PKS activities, we were unable to iden- 
tify the structure of those products. Moreover, the partially 
purified activities were not stable and were difficult to 
further purify. This result also has been encountered with 
other polyketide systems and researchers have relied on 
molecular analyses of mutants blocked in the pathway [6]. 
Identification of polypeptides missing in the mutants 
Crude extracts prepared from strains CW and BX102 
grown under production conditions gave nearly identical 
profiles of polypeptides using Coomassie-stained sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE), with the exception of an -2.50 kDa polypeptide 
that was absent in strain BX102. The -250 kDa polypep- 
tide was also present in a monacolin-J-producing mutant 
(PSlO) grown under production conditions, but was absent 
from cultures in the preproduction phase of growth. To 
visualize better these large polypeptides, organomercurial 
agarose chromatography was used to partially purify them. 
Protein eluted from such resin with 100 mM dithiothreitol 
was resolved using preparative SDS-PAGE. The 
-250 kDa polypeptide was extracted from the gel and used 
to raise rabbit polyclonal antiserum. By comparing differ- 
ent strains using this enrichment procedure and analyzing 
polypeptides using both stained SDS-PAGE and western 
blots, we were able to show that the -250 kDa polypeptide 
was completely absent from the BX102 mutant and that a 
different polypeptide of about 220 kDa was absent from 
the monacolin-J-producing mutants (Figure 3). Rabbit 
polyclonal antiserum was also raised against this -220 kDa 
polypeptide and used to verify that it was absent in the 
monacolin-J-producing mutants (data not shown). 
Cerulenin inactivates polyketide and fatty acid syn- 
thases by forming an irreversible covalent bond with the 
active-site cysteine in the ketoacyl synthase domain 
[l&13]. As mentioned above, cerulenin inhibits lovas- 
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Cell-free extracts from the lovastatin-production strain, but not the 
nonproducing mutant, can synthesize lovastatin in vitro. Cell-free 
extracts from (a) strain CW and (b) mutant BXI 02 were incubated 
with [14C]malonylCoA and other reaction components as described in 
the Materials and methods section. The reaction products were 
extracted with ethyl acetate and resolved using HPLC. Fractions were 
collected and the radioactivity was determined using liquid scintillation 
counting. LC, lovastatin carboxylate; LL, lovastatin lactone. 
using organomercurial agarose chromatography were incu- 
bated with [“Hlcerulenin and resolved using SDS-PAGE, 
and the labeled proteins subsequently detected by auto- 
fluorography of the gels, several polypeptides, including 
those of -220 and -250 kDa, became labeled (Figure 3). 
In agreement with results from the stained gels and 
western blots, both the -220 and -250 kDa polypeptides 
were present in strain CW, whereas strain PSlO was 
specifically missing the -220 kDa polypeptide and strain 
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Figure 3 
Mutants blocked in the lovastatin pathway 
are missing specific high molecular weight 
polypeptides that covalently bind cerulenin. 
(a) A Coomassie-dye-stained gel of extracts 
from production strain CW (lane 2) and 
mutant BX102 (lane 3) after enrichment by 
thiol agarose chromatography and 
ultracentrifugation (see the Materials and 
methods section). The -250 kDa 
polypeptide missing in mutant BX102 is 
indicated with an arrowhead. Lane 1 is a 
200 kDa protein standard (rabbit skeletal 
muscle myosin). (b) A western blot in which 
the gel was blotted to nitrocellulose, reacted 
with anti-250 kDa polypeptide antiserum and 
developed using alkaline phosphatase 
conjugated secondary antibody. Lane 1 is 
the gel-purified -250 kDa polypeptide, 
lane 2 is the extract from strain CW and 
lane 3 is the extract from mutant BX102. The 
lower molecular weight bands in lanes 1 and 
2 that cross react with the antiserum are 
proteolytic fragments of the -250 kDa 
polypeptide, because they are also seen in 
the purified protein preparation but do not 
correspond to any of the prominently staining 
bands present in the extract. (c) A 
Coomassie-dye-stained gel of 
organomercurial resin-enriched fractions 
(a) W Cc) W 
1 2 3 1 2 3 1 2 3 1 2 3 
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from strain CW (lane 2) and a triol-producing 
mutant (PSl 0) (lane 3). Lane 1 is the 
200 kDa protein standard. The -220 kDa 
polypeptide in lane 2 missing in mutant 
PSlO is indicated by the arrowhead. (d) An 
autofluorograph of a gel in which 
organomercurial resin-enriched fractions 
from strains CW (lane l), BX102 (lane 2) 
and PSlO (lane 3) were incubated with 
[3H]cerulenin for 60 min and the labeled 
polypeptides resolved using SDS-PAGE. In 
all these experiments the gels were precast 
4% acrylamide gels from Novex run under 
identical conditions. The position of a given 
polypeptide band in the four gel images is 
therefore similar. 
BX102 was missing the -250 kDa polypeptide, as well as 
another polypeptide of -230 kDa. Mutant BXlOZ also 
contained a strongly labeled polypeptide of -140 kDa not 
observed in strains CW or PSlO. It is unlikely that this 
-140 kDa cerulenin-labeled polypeptide is a fragment of 
either the -220 or -250 kDa polypeptides, as it was not 
observed on a western blot. It may represent another PKS 
(see below), or a proteolytic fragment thereof, that can 
only interact with cerulenin in the absence of the PKS 
represented by the -250 kDa polypeptide. These data 
suggest that the -250 and -220 kDa polypeptides repre- 
sent PKSs for synthesis of the nonaketide and diketide 
portions of lovastatin, respectively. The additional 
polypeptides that interact with cerulenin probably repre- 
sent P-ketoacyl synthases, or enzymes catalyzing similar 
reactions, other than those required for lovastatin biosyn- 
thesis. A 6-methylsalicylic acid synthase (6-MSAS) gene 
has been reported in A. te~ezrs [14] and there should be a 
PKS for the synthesis of emodin (the precursor to 
sulochrin produced by A. terre~s [l l]), plus possibly a PKS 
for synthesis of spore pigment, as seen in A. niddans [lS]. 
Cloning and sequencing the gene for the -250 kDa 
polypeptide 
Initial attempts to clone lovastatin PKS genes by hybridiza- 
tion to the ketoacyl synthase domain of the Penicdhm 
patuhm 6-MSAS gene [16] resulted only in cloning an 
A. terrezls 6-MSAS homolog. Genomic DNA from strain 
CW was therefore used to prepare a cosmid library in an 
AspPrgil~slEsc~e~c~~a c&i shuttle cosmid (pLO9), and the 
library was used to complement the BX102 mutation. Out 
of -6000 transformants of mutant BX102, one lovastatin 
producer was identified, from which the cosmid was recov- 
ered by in vitro packaging of its genomic DNA [17]. Four 
of 20 isolates transformed with this recovered cosmid were 
restored for production of lovastatin and the -250 kDa 
polypeptide, as analyzed using SDS-PAGE. Some trans- 
formants may not express the large PKS gene either 
because it is disrupted during the integration event [18] or 
because integration occurs at a silent chromosomal locus. 
In another approach, cDNA libraries prepared in the 
E. co/i vector hgtll using mRNA from a lovastatin-produc- 
ing culture were screened with the antiserum raised 
against the -250 kDa polypeptide. Using this approach, 
18 clones were isolated, several of which encoded one of 
two different ubiquitin homologs, possibly because the 
-250 kDa polypeptide used to prepare the antiserum had 
been ubiquitinated. Two cDNA clones were found that 
hybridized to the BXlOZ-complementing cosmid clone 
described above, however. The longer one (cDNAZ-9 that 
has a 2 kilobase (kb) insert) was found to contain a polyA 
tail, a 3’-untranslated region, and an open reading frame 
encoding the carboxyl terminus of a protein with an acyl 
carrier protein motif similar to those of P. pudvm 
6-methylsalicylic acid synthase [16] and rat fatty acid syn- 
thase [19]. The cDNA sequence also encoded the first of 
three amino acid sequences previously obtained from 
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Figure 4 
Structure of the LNKS gene and protein. (a) A 
map of the LNKS gene region with 5’ and 3’ 
noncoding regions shown in black and introns 
shown in red. Also shown are the locations of 
transcription start, polyadenylation and the 
catalytic sites (see below). (b) The conserved 
sequence motifs in LNKS compared with 
those of rat fatty acid synthase and 
P. patulum 6-methylsaiicylic acid synthase. 
Color-coded regions represent catalytic 
domains for P-ketoacyl synthase (KS; 42% 
identity with rat FAS over 231 residues), 
acetyllmalonyl transferase (AT; 300/o identity 
with rat FAS over 126 residues), dehydratase 
(DH; motif HALGGGTVFPAAG), methyl 
transferase (MT; see Figure 6) enoyl 
reductase (ER; not found in LNKS), 
b-ketoreductase (KR; 33% identity with rat 
FAS over 171 residues), acyl carrier protein 
(ACP; 31 ‘J/o identity with rat FAS over 45 
(a) Transcription start BamHl Polyadenylation 
Hindlll ECORI 
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residues) and the peptide synthetase positions of three peptide sequences (see 
elongation domain (PSED; see Figure 6). The text) obtained from the purified -250 kDa 
polypeptide are indicated above the LNKS 
sequence (Pl, P2 and P3). 
prominent 1ysC protease fragments of the -250 kDa poly- 
peptide (VLGGASITDLANEAA, TDRDANLFPT and 
TGITMPN; using single-letter amino acid code). 
The cDNAZ-9 clone was used to isolate a set of overlap- 
ping hEMBL3 clones from an A. terrezls genomic library, 
and the sequence of an 11.6 kb region was obtained. In 
addition, cDNA sequence was obtained from fragments 
amplified by the polymerase chain reaction (PCR) from a 
total cDNA pool using primers designed from the 
genomic sequence. Figure 4 shows the structure of the 
isolated gene, which we name lovastatin nonaketide syn- 
thase (LNKS). The gene contains seven short (53-81 base 
pairs; bp) introns having splice junction motifs typical of 
other fungal introns. Primer extension analysis revealed a 
predominant transcription initiation point, and a few 
minor ones nearby. Upstream of these were sequence 
motifs typical of eukaryotic promoters: the sequence 
TTAATA at -30 bp (relative to the transcription start) and 
the sequence CAAT at -80 bp. The predicted mRNA 
transcript is -10 kb in length and encodes a 3038 amino 
acid protein with a predicted molecular weight of 
269 kDa. This size agreed well with the estimated appar- 
ent size from SDS-PAGE (-250 kDa). All three amino 
acid sequences obtained from proteolytic fragments of the 
-250 kDa polypeptide were encoded in the gene. 
Lovastatin titer is affected by the expression level of the 
LNKS gene 
Transformation. of mutant BX10’2 with pLO9 containing 
the cloned LNKS gene as an 11 kb fragment restored 
lovastatin production, proving the direct involvement of 
this PKS gene in lovastatin production. The level of lovas- 
tatin produced by different transformants correlated with 
the level of the -2.50 kDa polypeptide accumulated in 
those strains (Figure S), suggesting that the abundance of 
LNKS polypeptide in the production strains is important 
for the high-production phenotype. 
Structural features of the lovastatin nonaketide PKS 
protein 
Figure 4 shows the relative positions of functional domains 
identified in LNKS compared with rat fatty acid synthase 
[19,20] and P. patuhm 6-methyl salicylic acid synthase 
[16]. The first third of LNKS contains conserved B-ketoa- 
cyl synthase, acyl transferase and dehydratase domains, 
spaced similarly between the three enzymes. The B-ketoa- 
cyl synthase and acetyl/malonyl transferase domains of 
LNKS are highly similar to their counterparts from other 
enzymes. The dehydratase domain is clearly identified in 
the nonaketide PKS by its characteristic motif [21,22]. The 
B-keto reductase and acyl carrier protein motifs of the non- 
aketide PKS are also well conserved and are spaced simi- 
larly as for other FASs and PKSs. As several carbons of 
dihydromonacolin L are fully reduced, a functional enoyl 
reductase (ER) domain was expected in LNKS. Although 
sufficient space was present in the LNKS sequence to 
accommodate an ER domain, no sequence motifs typical 
of such domains were identified. 
There are two sequence motifs found in the nonaketide 
PKS that are particularly noteworthy (Figure 6). One is a 
putative S-adenosyl methionine binding motif found 
between the putative dehydratase and enoyl reductase 
domains. Because S-[‘“Clmethyl methionine labels the 
C6 methyl group of lovastatin [ZA], an adenosyl-methio- 
nine-dependent methyl-transferase activity must be 
involved. Although methyl-transferase domains have 
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Figure 5 
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LNKS gene expression in transformants of mutant BX102 correlates 
with lovastatin production. Shown is a Coomassie-stained SDS gel of 
protein extracts enriched by organomercurial resin chromatography. 
Lane 1 is a 200 kDa protein standard. Samples were prepared from 
strain CW (lane 2), mutant BX102 (lane 3), and three transformants of 
BX102 in which lovastatin production was restored (lanes 4-6). 
Relative to CW the level of lovastatin produced by these strains was 
O%, 33%, 73% and 540/o, respectively. 
been seen in multifunctional peptide synthetases [23,24], 
we have not seen a report that identifies such a motif in a 
multifunctional PKS. The other motif of interest is at the 
carboxy-terminal end of the nonaketide PKS where, 
instead of a thioesterase domain, there is a domain with 
strong homology to the elongation domains of peptide 
synthetases, which catalyze peptide-bond formation. As 
there is no known role for amino acids, or other nitrogen- 
containing compounds, in lovastatin biosynthesis, the 
role of this carboxy-terminal domain of LNKS remains to 
be determined. 
Homologs of lovastatin nonaketide PKS in other fungi 
Several other fungi produce lovastatin-related structures, 
including M. r&r, which produces lovastatin [ZS], and 
Penicih’ium c&inum and P. hrmiconzpactum, which produce 
compactin [26,27]. Compactin is identical to lovastatin 
except that it is missing the methionine-derived methyl 
group on the nonaketide. Genomic DNA from these 
fungal species was analyzed using Southern blot 
hybridization to the ketoacyl synthase region of LNKS 
gene (Figure 7). Hybridization was to a single genomic 
region in A. terreus, M. mber and P. citrinum, indicating that 
in each of these strains there is only one gene closely 
related to LNKS. Blots containing DNA from P. brmicom- 
pacturn gave a complex pattern of hybridization that we 
could not interpret. A probe from A. terreus cDNA clone 
2-9 consisting of the acyl carrier protein and peptide syn- 
thetase domains of LNKS gave similar results. In contrast, 
a probe consisting of the putative methyl-transferase 
domain hybridized only to DNA from A. terreus and 
M. rmber, but not to DNA from P. citrinum or P. brevicom- 
pactum. This is consistent with the fact that these latter 
two species do not carry out the methylation reaction. 
Discussion 
Isotopic labeling studies [Z-4] and in V~UO biotransforma- 
tion of putative pathway intermediates [7-91 led to a 
hypothetical scheme for lovastatin biosynthesis. The 
results reported here are consistent with this scheme, 
and have suggested new enzymological details, as shown 
in Figure 1. The gene for a large (-250 kDa) polypeptide 
was cloned and found to encode a type I PKS that can 
complement mutant BX102, indicating that it was the 
proposed LNKS gene. A polypeptide of -220 kDa, 
which reacts covalently with cerulenin and is missing in 
mutants unable to synthesize the methylbutyryl group, 
probably represents LDKS, but definitive proof of this 
will require isolation of this gene. LNKS contains 
sequence motifs for catalytic functions expected for the 
synthesis of the nonaketide chain of lovastatin, and these 
are arranged in the same order as seen in other multi- 
functional polyketide and fatty acid synthases. Although 
there is sufficient space for an enoyl reductase domain at 
the amino-terminal end of the KR domain, a sequence 
signature motif representative of an ER was not seen. If  
LNKS does not encode an ER activity, this has impor- 
tant implications for the mechanism of synthesis of dihy- 
dromonacolin L. LNKS also has motifs that represent 
homologs of methyl transferases and the elongation 
domain of peptide synthetases, as discussed below. 
Biosynthesis of each polyketide chain of lovastatin 
includes one C-methylation reaction [24]. Because we 
found a mutant that accumulates monacolin X, C-methy- 
lation of the diketide presumably occurs prior to keto 
reduction, when the flanking carbonyls should facilitate 
carbanion formation. The existence of this mutant sug- 
gests that the activity normally responsible for the transfer 
of the methylbutyryl group to monacolin J also is capable 
of transferring the methylacetoacetyl group. The signifi- 
cant amount of monacolin J produced by this mutant sug- 
gests, however, that transfer of a methylacetoacetyl group 
from LDKS is less efficient than transfer of a methylbu- 
tyryl group, consistent with the substrate specificity seen 
for the putative methylbutyryl transferase in dro. 
The C-methylation required for the biosynthesis of 
monacolin J [Z-4] may be an integral function of LNKS 
on the basis of the presence of a methyl-transferase sig- 
nature sequence in LNKS. Although such a domain has 
not been reported in other PKSs, they are present and 
functional in several nonribosomal peptide synthetases 
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Figure 6 
Domains in LNKS homologous to methyl- 
transferase and peptide synthetase elongation 
domains. Sequences were aligned using 
default settings of the CLUSTAL algorithm in 
MacVector (Oxford Molecular). (a) Methyl- 
transferase sequences, with GenBank 
accession numbers, are: YP-HMWP, Yersinia 
pesfis high molecular weight protein 
(AF091251); YE-HMWP, Yersinia 
enteroolyticus high molecular weight protein 
(Y12527); PM-NRPS, Proteus m?ababi/is 
nonribosomal peptide synthetase (U46488); 
BS-PS, Bacillus subtilis polyketide synthase 
(Z99113). (b) Peptide synthetase elongation 
domain sequences are: TI-CS, Tolypocladium 
inflatum cyclosporin synthetase (232674); 
rapP, rapamycin pipecolate incorporating 
enzyme from Streptomyces hygroscopicus 
(X86780); PA-PS, Pseudomonas aeruginosa 
pyoverdine synthetase (AF002222); BS-PS, 
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[23,24]. In addition, BLAST searches with this sequence that this domain catalyzes methylation of the lovastatin 
found a hypothetical polyketide synthase in the Bacilh nonaketide chain during its assembly. Functional dissec- 
subtilis genome (see Figure 6), which also has a methyl- tion of this domain might be achieved by expressing 
transferase signature sequence. It is reasonable to propose chimeras of the A. terreb LNKS gene and the compactin 
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Figure 7 
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Potential homologs of the LNKS gene in other fungi. Shown is an 
autoradiogram of a genomic Southern blot using a probe consisting of 
a gel-isolated 1 kb Pstl fragment from the LNKS gene labeled by 
random oligonucleotide priming. The position of DNA size markers on 
the gel is indicated on the left. Lanes l-4, A. terreus DNA cut with 
SalI, Sacl, Pvull and /WI, respectively. Lanes 5-6, M. ruber DNA cut 
with .%/I, Sacl, Pvull and Pstl, respectively. Lanes 9-l 1, f. citrinum 
DNA cut with Sall, Sacl and Pvull, respectively. 
nonaketide synthase gene of P. citrinum, which should not 
have a functional methylation domain. 
An interesting feature of the nonaketide portion of lovas- 
tatin is the relatively reduced state of the first six acetate 
units in the chain, and the relatively unreduced state of 
the last three. Formation of the hexahydronaphthalene 
ring system has been postulated to involve an intramolec- 
ular Diels-Alder condensation [Z-S]. I f  the nonaketide 
PKS is solely responsible for synthesis of dihydromona- 
colin L, this enzyme represents one of the most sophisti- 
cated iterative PKSs known. Aside from the additional 
domains to catalyze the C-methylation and Diels-Alder 
condensation, the enzyme apparently uses its dehy- 
dratase domain selectively. Does this depend on chain 
length, or perhaps the Diels-Alder condensation? 
Yoshizawa et al. [3] have proposed a possible reaction 
sequence for dihydromonacolin L in which the chain is 
partially synthesized, the Diels-Alder condensation 
occurs and finally the chain is completed. Although we 
were unable to identify any of the several products pro- 
duced by the partially purified PKS fractions, none comi- 
grated with dihydromonacolin L, the putative first 
intermediate in the nonaketide pathway [7-91. Recently, 
Hutchinson, Vederas and their colleagues [28] have 
determined the structure of molecules produced by A. 
niddans heterologously expressing the A. terreus LNKS 
gene. Their work suggests that LNKS might produce a 
precursor of dihydromonacolin L that requires at least 
one other enzyme to complete the synthesis. 
Following the acyl carrier domain, the nonaketide PKS 
contains an unusually long carboxy-terminal region that 
shares significant homology to elongation domains of 
peptide synthetases. These domains presumably catalyze 
attack of the acyl thioester on one phosphopantetheine by 
the amino group of an amino acid on an adjacent phospho- 
pantetheine [23,24]. Such a domain also might catalyze 
condensation or transfer through a nucleophile other than 
an amino group, however. There is considerable paral- 
lelism between polyketide and nonribosomal peptide syn- 
thesis [29] and there are examples of molecules, such as 
rapamycin and bleomycin, that are constructed of both 
amino acid and acyl extender units. 
Hutchinson and colleagues [ZS] have recently sequenced 
the lovastatin biosynthetic gene cluster of A. terreds and 
have identified several genes surrounding the LNKS gene 
with roles in lovastatin biosynthesis. We have previously 
identified an enzyme that may catalyze transfer of the 
methylbutyryl group from LDKS to monacolin J and a can- 
didate gene for this enzyme was found in the cluster. In 
sterigmatocystin biosynthesis transfer of a hexanoyl chain 
from a specialized fatty acid to a PKS has been proposed 
[ZO]. The PKS completes the chain, skipping all reductions 
to give a putative polyketide intermediate that is fully 
reduced at one end and fully unreduced at the other 
[30,31]. The N-acetyl cysteamine derivative of hexanoic 
acid is efficiently incorporated into the sterigmatocystin 
precursors, but not if one of the genes for the specialized 
FAS is disrupted [30]. This implies interaction between 
the FAS and the PKS for labeling to occur and also sug- 
gests transfer of the hexanoyl group from the FAS to the 
PKS. Among the lovastatin biosynthetic genes found by 
Hutchinson and coworkers, none is a candidate for a third 
PKS that might ‘finish the monacolin L chain by a mecha- 
nism similar to that just described. Instead, LNKS may 
undergo a conformational (or covalent) change prior to the 
last two acyl condensations, in order to ensure that only 
keto reduction occurs after those final condensations. 
Significance 
The manipulation of polyketide biosynthetic genes has 
provided novel structures, many of potential pharmaceu- 
tical value, that would be difficult and expensive to 
obtain by synthetic chemistry. Fungal polyketide syn- 
thases (PKSs) have been less well studied than the PKS 
systems of actinomycetes despite the fact that they have 
unique features and produce unusual polyketides. The 
mechanistic enzymology of fungal PKSs is interesting, 
particularly how such enzymes use their catalytic sites 
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selectively depending on the structure of the product 
during its iterative assembly. This work paves the way 
for detailed studies leading to an understanding of the 
biosynthesis of an economically important natural 
product, lovastatin. We have provided evidence that the 
lovastatin nonaketide synthase contains catalytic 
domains not previously seen in PKSs: one for C-methy- 
lation and one for an activity related to nonribosomal 
peptide synthesis. 
Materials and methods 
Strains and culture conditions 
The A. terreus strains used in this work were derived from an industrial 
strain development program described previously [l 1,321. Strains were 
maintained on YME media (0.4% yeast extract, 0.1% malt extract, 0.4% 
glucose, 5 ppm FeS0,,7H,O, 2% agar, pH 7.2). A two-stage shake 
flask procedure for lovastatin production was used, as described previ- 
ously [l 1,321. Lovastatin was extracted from cultures with two volumes 
of ethanol followed by dilution with methanol and filtering prior to analy- 
sis Radiolabeled lovastatin and lovastatin precursors were prepared by 
adding [14Clglucose to resting cultures of selected strains and isolat- 
ing, using semipreparative HPLC, the desired compounds. Resting cul- 
tures were prepared by washing and resuspending mycelia from a 
production culture in 50 mM Tris, pH 7.5 to 3x the original density. 
Analytical methods 
HPLC analysis of metabolites from A. terreus used a Waters system 
with a Cl8 Novapak radial compression cartridge and photodiode 
array detector. Mobile phases (at 1.5 ml/min) were A: acetonitrile with 
0.02% trifluoroacetic acid and B: distilled water with 0.02% trifluo- 
roacetic acid. Initial conditions were 35% A, 65% B. After sample 
injection, there was a 3 min linear gradient from initial conditions to 
65% A, 35% B followed by 4 min at those conditions. Lovastatin and 
related metabolites were detected by their absorbance maximum at 
238 nm. A reference standard of lovastatin was provided by Merck. 
Monacolin J was prepared from lovastatin by hydrolysis in 0.1 M LiOH 
at 95°C. The identity of monacolin X and monacolin L was verified 
using 13C and proton NMR spectrometry. 
Preparation of cell-free extracts and enzyme assays 
Mycelia from production cultures were harvested on Miracloth, washed 
with cold water, lyophilized and pulverized in extraction buffer (20 mM 
Tris pH 8.0, 10% glycerol, 1 M NaCI, 5 mM ascorbate, 1 mM EDTA, 
1 mM DTT, 3.8 pglml leupeptin, 17.7 uglml chymostatin, 2.0 l.rg/ml 
pepstatin, 0.2 mM PMSF, 2.2% polyvinyl polypyrrolidone) by grinding 
with glass in a mortar and pestle. The homogenate was centrifuged at 
10,000 g for 10 min to give a crude cell-free extract. PKS and FAS 
activities were assayed in crude or partially purified protein fractions by 
incubating with a labeled substrate and other required factors, extract- 
ing with ethyl acetate, and analyzing the labeled products using TLC or 
HPLC. The standard reaction mixture was 50 ~1 containing 50 mM 
Tris, pH 7.5, 0.1 PM [14C]malonyl-CoA (-4 x 1 O5 cpm), 300 uM 
acetyl-CoA, 1 mM S-adenosyl methionine, 0.1 mM NADPH, and 
0.1 mM ATP. After incubation at 28°C for 1 h, the resulting products 
were extracted twice with ethyl acetate, samples were dried, taken up 
in methanol, and products resolved using HPLC (see above) or using 
chromatography on thin layer silica plates developed with a solvent of 
90% CH,CI, and 10% methanol containing 1 M acetic acid and 1 M 
ammonium acetate. Radioactive products on TLC plates were visual- 
ized by autoradiography, whereas radioactivity in HPLC fractions was 
determined by scintillation counting. 
Isolation of high molecular weight polypeptides 
Crude cell-free extract was prepared as described earlier except the 
lyophilized mycelia was first washed with acetone. For analytical 
experiments crude extract was applied directly to an organomercurial 
agarose (Bio-Rad Affi-gel 501) column equilibrated in Buffer A 
(20 mM Tris, pH 8; 50 mM NaCl; 5 mM EDTA; 5 mM ascorbic acid). 
The column was washed with 5 vol buffer A, 10 vol buffer A containing 
0.5 M NaCI, and 5 vol buffer A. Bound proteins were eluted with 40 ml 
buffer A containing 100 mM DlT. Samples were concentrated and 
dialyzed for SDS-PAGE analysis. For preparation of polypeptide 
antigen, proteins were precipitated from the crude extract with 16% 
PEG 3,000 followed by centrifugation at 30,000 g for 30 min and 
applied to an organomercurial agarose (Bio-Rad Affi-Gel 501) column. 
Protein eluted from the column was subjected to ultracentrifugation at 
180,000 g for 16 h. The supernatant was discarded and the protein 
pellet dissolved in gel loading buffer consisting of 125 mM Tris, 
pH 6.8; 10% glycerol; 0.005% bromphenol blue; 2% SDS; 0.6 M 2- 
mercaptoethanol and heated to 95°C for 10 min. The sample was 
electrophoresed on a preparative 1.5 mm, 4% acrylamide SDS gel 
(Novex) at 14OV for 2 h using electrode buffer consisting of 25 mM 
Tris; 192 mM glycine; 0.1% SDS. Electrophoresis was stopped when 
the prestained 200 kDa reference standard was 1.4 cm from the 
bottom of the gel. To visualize proteins the gel was rinsed briefly with 
water, soaked in 0.2 M imidazole for 10 min, transferred to 0.3 M zinc 
acetate for 5 min and finally rinsed with water. Stained bands of the 
desired size were excised from the gel and destained in 0.25 M Tris, 
0.25 M EDTA, pH 9.5 for 5 min until the slice became transparent. 
To generate antisera destained gel slices were crushed between glass 
plates and forced sequentially through 18 and 25 gauge needles. A 
0.5 ml aliquot of this material was mixed with an equal volume of Fre- 
und’s complete adjuvant and injected into rabbits. Boosts at 21 and 
42 days used material prepared as described, but with 0.5 ml Freund’s 
incomplete adjuvant. Antibody was affinity purified by immobilizing the 
antigen on PVDF membrane by electro-transfer from a preparative SDS 
polyacrylamide gel. The area of the membrane containing the polypep- 
tide of interest was cut out, incubated in lTBS (50 mM Tris, pH 7.5; 
0.5 M NaCI, 0.05% Tween 20) plus 5% non-fat dry milk for 1 h, and 
washed 3x for 5 min in TTBS. The immobilized antigen was incubated 
for 5 h with 2 ml of antisera diluted 1 :l with TTBS plus 1% non-fat dry 
milk. The membrane was washed 4x 10 min with TTBS, and the bound 
antibody was eluted with 2 ml of 0.1 M glycine, pH 2.8. The eluted anti- 
body was neutralized with 50 pl of 1 .O M Tris, pH 9.5. 
High molecular weight polypeptides were resolved using SDS-PAGE 
(Novex 1 mm 4% acrylamide gels). For western blots, proteins were 
electrophoretically transferred to nitrocellulose in 25 mM Tris, 192 mM 
glycine, pH 8.3, 20% methanol, 0.05% SDS at 240 mA for 2 h. Blots 
were rinsed for 1 min in TTBS then blocked for 2 h in TTBS with 5% 
non-fat dry milk. incubation with primary antibody was for 16 h at a 
1 :l 000 dilution of antisera in TTBS containing 1 o/, nonfat dry milk. The 
blot was washed in TTBS 3x for 5 min each and incubated with goat 
antirabbit alkaline phosphatase conjugate diluted 1:lOOO for 2 h in 
TTBS containing 1% nonfat dry milk. After washing 4x 10 min in lTBS, 
color development was achieved with 5-bromo-4-chloro-3 indolyl phos- 
phate (1 15 pg/ml) and nitroblue tetrazolium (330 pg/ml) in 66 mM Tris, 
pH 9.5; 0.1 M NaCI; 5 mM MgCI,. 
Isolation of nucleic acids 
To isolate genomic DNA, lyophilized mycelia were ground dry with 
sand in a mortar and pestle, mixed with lysis buffer (100 mM NaCI; 
50 mM EDTA; 10 mM Tris, pH 8.0; 1% SDS; 50 pglml pancreatic 
RNase; 50 pglml Proteinase K) and extracted with an equal volume of 
Tris-saturated phenol-chloroform by gently shaking for 1 h at 37°C. 
Upon centrifugation at 8,000 g for 10 min, the extraction was repeated 
with phenol-chloroform, followed by chloroform. DNA was precipi- 
tated with ethanol and resuspended in TE (10 mM Tris-HCI, 1 mM 
EDTA, pH 7.5). 
To isolate RNA, production culture mycelia was collected on Miracloth, 
washed with distilled water and quickly frozen in liquid nitrogen. Frozen 
mycelia was ground to a fine powder with glass in a mortar and pestle 
under liquid nitrogen, The frozen powder was added to 50 mM Tris 
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pH 7.4, 150 mM NaCI, 5 mM EDTA, 5% SDS and the mixture 
extracted twice with phenol/chloroform. The final aqueous layer was 
brought to 3 M LiCI, kept at -20°C for 4 h, centrifuged at 12,000 xg for 
20 min and the pellet resuspended in RNase-free water. Polyadeny- 
lated RNA was isolated by chromatography on oligo-d(T) cellulose 
according to the manufacturer’s instructions (Poly(A)QuikM mRNA 
purification kit from Stratagene). 
Library construction 
The cosmid library was prepared in PLO9 (see below) by ligation to 
separate left and right arms 1331, packaged using the GigaPak Gold kit 
(Stratagene) and transfected into E. co/i DH5o. PLO9 was constructed 
from pUCl8, a modified A. niger P-tubulin promoter fragment, the 
phleomycin resistance gene plus yeast CYCl gene terminator cassette 
from pUT713 (Cayla), and a Pstl fragment from pBTI-1 (Boehringer- 
Mannheim) containing the hcos site. To prepare cosmid DNA with full 
representation for transforming BX102, f. co/i cells carrying the library 
were plated at confluence, cells were scraped from the plates in 10 ml 
of cold 50 mM Tris pH 8.0, 100/o sucrose, and DNA was isolated by 
gentle SDS lysis and purified by CsCl density gradient centrifugation 
[33]. Vector DNA with insert was isolated from vector DNA without 
insert by resolution on 0.5% agarose gels. The phage genomic library 
was prepared using predigested EMBL3 arms (Promega), packaged 
with GigaPak Gold (Stratagene), and transfected into f. co/i LE392. 
Polyadenylated RNA was used to construct two cDNA libraries in 
hgtl 1 using the Superscript Choice System (BRL) according to the 
manufacturer’s instructions. First strand synthesis was primed using 
either 0.05 ug random hexamers plus 0.5 pg oligo(dT)12-18 or 1 ug 
oligo(dT)12-18 alone. E. co/i strain Y1090 was used as the host. To 
decrease cross reaction to f. co/i proteins the antisera was pre- 
reacted with a lysate of Y1090 cells and this antiserum was used to 
screen the hgtl 1 library [33]. 
Sequencing 
Raw sequence data was generated using an Applied Biosystems 
373A automated DNA sequencer according manufacturer’s proto- 
cols. Genomic clones were sequenced from randomly selected 
clones of l-2 kb fragments and by oligonucleotide primer walking. 
cDNA was sequenced from PCR products generated using primers 
designed from the genomic sequence. The sequence was assembled 
using the SeqMan program (Lasergene package from DNA Star) on a 
Macintosh computer. 
Transformation of A. terreus 
To prepare spheroplasts of A. terreus, 10s spores were inoculated into 
50 ml CM media in a 250 ml flask and cultures were grown for 30 h at 
200 rpm and 28°C. Mycelia was collected on Miracloth and 4 g was 
suspended in 100 ml KMP (700 mM KCI, 800 mM mannitol, and 
20 mM potassium phosphate, pH 6.3). Trichoderma harzianum lysing 
enzymes (100 mg; Sigma) were added and the flask was shaken at 
100 rpm for 18 h at 28%. Spheroplasts were filtered through Miracloth 
into 50 ml conical centrifuge tubes, concentrated by centrifugation at 
100 g, and washed twice by suspending in 15 ml of KCM (700 mM 
KCI; 10 mM MOPS adjusted to pH 5.8) and centrifuging. Washed 
spheroplasts were suspended at 5 x 107/ml in KCMC (KCM brought 
to 50 mM CaCI, just prior to use). For transformation, 6.5 pl of KCMC 
containing 5 units of heparin was added to a tube containing 5 ug of 
vector DNA in 20 ul TE. The spheroplast suspension (200 ul) was 
added, followed by 50 ul of PCM (40% PEG-8000, 10 mM MOPS, 
pH 5.8, 50 mM CaCI,) and the suspension incubated on ice for 
30 min. The spheroplast suspension was diluted with 0.6 ml PCM, 
transferred to 50 ml of melted MA (5% Clutterbuck’s salts, 0.5% tryp- 
tone, 0.5% yeast extract, 1.0% glucose, 23% mannitol, 2% agar) main- 
tained at 45”C, and immediately distributed into five tared petri dishes. 
After incubation at 28°C for 4 h, each plate was overlayed with an 
equal volume of overlay agar (1% peptone, 1% agar, 100 pg/ml 
phleomycin) and incubated at 28% until sporulating colonies could be 
picked (7-l 0 days). 
Accession numbers 
The accession number of the LNKS sequence is Genbank AFl51722. 
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